[go: up one dir, main page]

ES2164310T3 - Comprimidos matriciales para uso oral y de liberacion prolongada que contienen la sal sodica de la tianeptina. - Google Patents

Comprimidos matriciales para uso oral y de liberacion prolongada que contienen la sal sodica de la tianeptina.

Info

Publication number
ES2164310T3
ES2164310T3 ES97400911T ES97400911T ES2164310T3 ES 2164310 T3 ES2164310 T3 ES 2164310T3 ES 97400911 T ES97400911 T ES 97400911T ES 97400911 T ES97400911 T ES 97400911T ES 2164310 T3 ES2164310 T3 ES 2164310T3
Authority
ES
Spain
Prior art keywords
tianeptine
sodium salt
marriage
tablets
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97400911T
Other languages
English (en)
Inventor
De Barochez Bruno Huet
Patrick Wuthrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Application granted granted Critical
Publication of ES2164310T3 publication Critical patent/ES2164310T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A UN COMPRIMIDO MATRICIAL PARA LA LIBERACION PROLONGADA DE LA SAL DE SODIO DE TIANEPTINA QUE GARANTIZA UNA LIBERACION CONTINUA Y REGULAR DEL PRINCIPIO ACTIVO TRAS LA ADMINISTRACION POR VIA ORAL.
ES97400911T 1996-04-24 1997-04-23 Comprimidos matriciales para uso oral y de liberacion prolongada que contienen la sal sodica de la tianeptina. Expired - Lifetime ES2164310T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9605174A FR2747921B1 (fr) 1996-04-24 1996-04-24 Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale

Publications (1)

Publication Number Publication Date
ES2164310T3 true ES2164310T3 (es) 2002-02-16

Family

ID=9491549

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97400911T Expired - Lifetime ES2164310T3 (es) 1996-04-24 1997-04-23 Comprimidos matriciales para uso oral y de liberacion prolongada que contienen la sal sodica de la tianeptina.

Country Status (18)

Country Link
US (1) US5888542A (es)
EP (1) EP0803253B1 (es)
JP (1) JPH1036268A (es)
CN (1) CN1116029C (es)
AT (1) ATE205715T1 (es)
AU (1) AU719822B2 (es)
CA (1) CA2203310C (es)
DE (1) DE69706748T2 (es)
DK (1) DK0803253T3 (es)
ES (1) ES2164310T3 (es)
FR (1) FR2747921B1 (es)
GR (1) GR3037043T3 (es)
HU (1) HU224192B1 (es)
NO (1) NO315407B1 (es)
NZ (1) NZ314662A (es)
PL (1) PL188135B1 (es)
PT (1) PT803253E (es)
ZA (1) ZA973495B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2791891A1 (fr) * 1999-04-07 2000-10-13 Adir Utilisation de la tianeptine pour l'obtention de medicaments destines au traitement des pathologies de la neurodegenerescence
US6683072B1 (en) 2003-02-04 2004-01-27 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of irritable bowel syndrome and nonulcer dyspepsia
SI1575565T1 (sl) * 2003-08-08 2010-04-30 Biovail Lab Int Srl Tableta bupropion hidroklorida z modificiranim sprošŽŤanjem
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
US20100304391A1 (en) * 2009-05-29 2010-12-02 Lombard Jay L Methods for assessment and treatment of depression via utilization of single nucleotide polymorphisms analysis
US20110237537A1 (en) * 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
KR20120092993A (ko) * 2011-02-14 2012-08-22 지엘팜텍 주식회사 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
PL2561864T3 (pl) * 2011-08-25 2015-05-29 Zakl Farmaceutyczne Polpharma Sa Tabletka powlekana zawierająca tianeptynę i sposób jej otrzymywania
KR101136976B1 (ko) * 2011-09-06 2012-05-30 건일제약 주식회사 티아넵틴 또는 그의 염을 포함하는 탈모증의 예방 또는 치료용 약학 조성물
GB201208315D0 (en) 2012-05-11 2012-06-27 Numedicus Ltd Pharmaceutical methods and compositions
CN104031005B (zh) * 2014-05-30 2016-04-27 济南诚汇双达化工有限公司 一种噻萘普汀钠中间体的制备方法
KR20180101307A (ko) 2018-09-04 2018-09-12 지엘팜텍주식회사 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
KR20200104265A (ko) 2020-08-21 2020-09-03 지엘팜텍주식회사 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
AU2024245246A1 (en) 2023-03-27 2025-10-30 Tonix Pharma Limited (s)-tianeptine and use in treating disorders and conditions associated with peroxisome proliferator-activated receptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
FR2635461B1 (fr) * 1988-08-18 1992-01-17 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
FR2716623B1 (fr) * 1994-02-25 1996-08-23 Adir Utilisation d'un dérivé tricyclique pour l'obtention de médicaments destinés au traitement des troubles mnémo-cognitifs.

Also Published As

Publication number Publication date
AU719822B2 (en) 2000-05-18
CN1116029C (zh) 2003-07-30
GR3037043T3 (en) 2002-01-31
US5888542A (en) 1999-03-30
CA2203310A1 (fr) 1997-10-24
PL188135B1 (pl) 2004-12-31
PL319627A1 (en) 1997-10-27
HUP9700806A2 (hu) 1998-10-28
NZ314662A (en) 1998-12-23
FR2747921A1 (fr) 1997-10-31
NO315407B1 (no) 2003-09-01
HUP9700806A3 (en) 2000-01-28
ATE205715T1 (de) 2001-10-15
EP0803253B1 (fr) 2001-09-19
DK0803253T3 (da) 2001-11-19
NO971860L (no) 1997-10-27
CA2203310C (fr) 2001-10-23
CN1168792A (zh) 1997-12-31
HU9700806D0 (en) 1997-06-30
JPH1036268A (ja) 1998-02-10
ZA973495B (en) 1997-11-18
DE69706748T2 (de) 2002-07-04
AU1904197A (en) 1997-10-30
HU224192B1 (hu) 2005-06-28
DE69706748D1 (de) 2001-10-25
EP0803253A1 (fr) 1997-10-29
FR2747921B1 (fr) 1998-10-30
NO971860D0 (no) 1997-04-23
PT803253E (pt) 2001-12-28

Similar Documents

Publication Publication Date Title
ES2164310T3 (es) Comprimidos matriciales para uso oral y de liberacion prolongada que contienen la sal sodica de la tianeptina.
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
ES2159591T3 (es) Composicion de liberacion controlada.
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
ES2162517T3 (es) Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
ES2187822T3 (es) Comprimidos de disgregacion rapida.
IT1276689B1 (it) Forma farmaceutica solida ad uso orale
PE8298A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol para administracion oral
NO20003219L (no) Oral farmasøytisk doseringsform med pulsert frigivningsvirkning
NO20003218D0 (no) Oralfarmasøytisk doseringsform med forlenget frigivningsvirkning
PA8559501A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
ES2195638T3 (es) Preparaciones de combinaciones farmaceuticas en forma solida de dosificacion que contienen cardevilol e hidroclorotiazida.
ES2176106B1 (es) Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
ES2168241T1 (es) Preparacion farmaceutica que contiene tolperisona para administrar por via oral.
PA8625001A1 (es) Composiciones de pelicula
ES2174293T3 (es) Microesferas farmaceuticas de acido valproico para la administracion oral.
DK1007006T3 (da) Formulering af cefadroxilmonohydrattablet
ES2143481T3 (es) Comprimido de valproato de sodio de liberacion lenta.
HN2001000262A (es) Kit de repinotano
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
PA8523101A1 (es) Composicion de eletriptan en forma de particulas
GT200300249A (es) Administracion dermica de un inhibidor de ciclooxigenasa-2 selectivo soluble en agua
AR025792A1 (es) Formulaciones orales de liberacion controlada
AR017664A1 (es) Formulaciones farmaceuticas de liberacion sostenida que contienen inhibidores de la alfa-glucosidasa y su uso para la manufactura de un medicamento

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 803253

Country of ref document: ES